Enterprise Value

2.71B

Cash

283.4M

Avg Qtr Burn

-89.18M

Short % of Float

12.05%

Insider Ownership

12.85%

Institutional Own.

85.94%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Troriluzole (BHV-4157) Details
Obsessive compulsive disorder

Phase 3

Data readout

Troriluzole Details
Spinocerebellar Ataxia

Phase 3

Update

BHV-7000 Details
Bipolar disease, Epilepsy

Phase 2/3

Data readout

BHV-7000 Details
Major depressive disorder

Phase 2

Data readout

Phase 2

Initiation

Phase 2

Initiation

BHV-8000 [TYK2/JAK1 Inhibitor] Details
Central nervous system illness

Phase 2

Initiation

BHV-1510 Details
Cancer, Epithelial Tumors

Phase 1/2

Data readout

BHV-1300 Details
Rheumatoid arthritis

Phase 1

Data readout